Ga‑68 PSMA PET/CT for Detection of Metastatic Prostate Cancer

Detection Performance at Low PSA Levels

In men with biochemical recurrence, Ga‑68 PSMA PET/CT identifies metastatic disease in 33 % of patients with PSA 0–0.19 ng/mL and 45 % of patients with PSA 0.2–0.49 ng/mL, outperforming conventional imaging modalities. 1
Across PSA strata, detection rates increase progressively: 33–42 % (PSA 0–0.2 ng/mL), 45–58 % (PSA 0.2–0.5 ng/mL), 59–76 % (PSA 0.5–1.0 ng/mL), 75–76 % (PSA 1–2 ng/mL), and 93–95 % (PSA > 2 ng/mL). These figures are derived from pooled data in two independent studies. 1, 2
Compared with choline‑based PET tracers, Ga‑68 PSMA PET/CT shows significantly higher sensitivity at low PSA levels, reducing false‑negative findings in early biochemical recurrence. 2

Per‑patient sensitivity 77 % and specificity 97 % for nodal disease, indicating reliable identification of patients with lymph‑node involvement. 3
Per‑lesion sensitivity 75 % and specificity 99 %, demonstrating accurate localization of individual metastatic nodes. 3
Ga‑68 PSMA PET/CT is superior to conventional CT, whose nodal sensitivity falls below 40 %. 3

For bone lesions, the modality achieves per‑lesion sensitivity 83 % and specificity 95 %, markedly better than planar bone scintigraphy. 4

The European Association of Urology (EAU) guidelines endorse PSMA PET/CT, citing a 27 % higher overall accuracy versus combined CT + bone scan (92 % vs 65 %). 3
Sensitivity improves from 38 % (conventional imaging) to 85 % with PSMA PET/CT, while specificity rises from 91 % to 98 %. 3
Use of PSMA PET/CT leads to management changes in 28 % of patients, compared with 15 % when conventional imaging is employed. 3
Radiation exposure is reduced (8.4 mSv vs 19.2 mSv) when PSMA PET/CT replaces CT + bone scan. 3

Initial staging: For high‑risk localized or locally advanced prostate cancer, PSMA PET/CT is strongly recommended as first‑line imaging. 3
Intermediate‑risk disease (ISUP grade group 3): PSMA PET/CT is recommended when available. 3
Low‑risk disease: Additional imaging is not indicated. 3
Biochemical recurrence: PSMA PET/CT is the preferred imaging modality regardless of PSA level, with detection rates of 33–45 % even when PSA < 0.5 ng/mL, supporting its use when results will influence treatment decisions. 1, 2

Spatial resolution: Metastatic lymph nodes smaller than 4–5 mm may be missed, reflecting an inherent PET limitation rather than tracer performance. 3
Androgen deprivation therapy (ADT) can decrease PSMA expression, potentially lowering tracer uptake and causing false‑negative scans. 1
Heterogeneous PSMA expression among tumors may lead to false‑negative results in lesions with low target density. 1
Benign PSMA uptake (e.g., tracer trapping) can generate false‑positive findings, necessitating careful interpretation. 1

A short PSA doubling time (< 6 months) is associated with higher detection rates on PSMA PET/CT, independent of absolute PSA value. 2

The European Association of Urology (EAU) strongly recommends PSMA PET/CT for metastatic screening in high-risk localized or locally advanced prostate cancer, with a strong recommendation 5, 6
Ga-68 PSMA PET shows high sensitivity (77%) and specificity (97%) on a per-patient basis for lymph node involvement, according to the European Urology guidelines 5
On a per-lesion basis, Ga-68 PSMA PET demonstrates 75% sensitivity and 99% specificity for lymph node metastases, as reported in European Urology 5
PSMA PET/CT (regardless of radiotracer) is significantly more accurate than conventional imaging for identifying pelvic lymph nodes and distant metastases, with a higher accuracy rate, as stated in European Urology and Journal of Clinical Oncology 5, 7

The European Association of Urology (EAU) recommends PSMA PET/CT for intermediate-risk disease with ISUP grade group 3, if available, to increase accuracy, with a weak recommendation 5, 6
PSMA PET/CT has demonstrated 27% higher accuracy than conventional imaging (CT and bone scintigraphy) for identifying metastases, according to European Urology 5, 8
PSMA PET/CT prompts management changes more frequently than conventional imaging (28% vs. 15% of patients), with a significant impact on patient management, as reported in European Urology 5

Ga-68 PSMA PET/CT remains a highly effective imaging modality for prostate cancer staging and is more widely available in many centers, as stated in European Urology and Journal of Clinical Oncology 5, 7
Small lymph node metastases under the spatial resolution of PET may still be missed regardless of the tracer used, which is a potential pitfall, according to European Urology 5
The clinical impact of detecting additional small metastatic lesions with F-18 PSMA compared to Ga-68 PSMA on patient outcomes remains to be determined, as reported in European Urology 5